Amarin files 'free speech' suit against FDA
This article was originally published in Scrip
Executive Summary
Amarin has filed a lawsuit against the FDA in the US District Court for the Southern District of New York charging the agency's regulations restrict the company’s free speech rights to discuss off-label use of the firm's fish oil pill Vascepa (icosapent ethyl).